Urological Education Disclaimer
This suite is a Deterministic Educational Sandbox for demonstration and training. It is NOT a clinical diagnostic tool and should NOT be used for actual patient treatment. Clinical decisions must be made by qualified medical professionals based on individualized assessment. Not for Clinical Use.
PCa - Hormonal Therapy
Educational Sandbox
Created by Dr. Sharad Maheshwari
imagingsimplified@gmail.com
Clinical Parameters
System ready for
analysis
Processing Logic...
Safety Intercept: Flare Risk
Clinical logic has blocked Agonist initiation. High-burden metastatic disease requires immediate non-flare suppression or confirmed anti-androgen cover to prevent clinical flare symptoms.
STATUS:
TRACE_ID:
Calculated via Deterministic Decision Engine
ADT Pharmacology & Dosing
Comparative Analysis & Standard Depot Intervals
| Dimension | Localized Focus | Metastatic Focus |
|---|---|---|
| Clinical Intent | Curative intensification (Adjuvant to RT) | Lifelong suppression / Disease control |
| Duration Cycle | Defined (6m, 18m, 36m) | Lifelong / Indefinite |
| Flare Profile | Surge usually low clinical impact | Mandatory Anti-Androgen Shield |
| Common Dosages |
1-Month Cycle Leuprolide 7.5mg (SC) 3-Month Cycle Leuprolide 22.5mg (SC) 6-Month Cycle Leuprolide 45mg (SC) |
|
Patient Counselling
Managing Flare
Explain the 1-week testosterone surge. Reassure that initial bone pain increase or urinary hesitancy is a temporary effect managed via anti-androgens.
Metabolic Balance
Counsel on diet and physical activity. Muscle loss and fat redistribution are primary side effects. Monitor BP and Glucose regularly.
Bone Preservation
Calcium (1200mg) and Vitamin D (800-1000IU) supplementation. Weight-bearing exercise is critical to mitigate bone loss.
Monitoring Strategy
"Castration is defined as Serum Testosterone <50 ng/dL. Baseline monitoring and cardiovascular risk assessment are key for long-term ADT survivorship."
Comments
Post a Comment